APTAMER GRP. ORD 0.1P overview

Aptamer Sciences Inc. Files IND Application for Innovative Liver Cancer Treatment AST-201: A Promising Approach to Address Under Medical Needs PR Newswire SEONGNAM, South Korea, March 25, 2024 SEONGNAM, South Korea , March 25, 2024 /PRNewswire/ -- Aptamer Sciences Inc. (KOSDAQ, 291650) announced the filing of an Investigational New Drug (IND) application for the phase 1 clinical trial of AST-201 with the Korean Ministry of Food and Drug Safety on March 12th, 2024 . AST-201, the company's...

GUELPH, ON / ACCESSWIRE / July 27, 2023 / Zentek Ltd. (" Zentek " or the " Company ") (NASDAQ:ZTEK)(TSXV:ZEN), a technology development and commercialization company and McMaster University (McMaster) are proud to announce that Dr. Yingfu Li and his team at the Li Lab have developed a novel aptamer technology that increases the binding affinity of aptamers by up to 250 times. The increased binding affinity enhances the limits of detection for aptamer-based diagnostics. In addition, the enhanced...

10 January 2023 Aptamer Group plc (“ Aptamer ”, the “Company” or the “Group”) Appointment of Interim Chief Commercial Officer Aptamer Group plc (AIM: APTA), the developer of novel Optimer ® binders to enable innovation in the life sciences industry, today announces the appointment of Derek Smith as Interim Chief Commercial Officer, effective as of 1 st January 2023. Derek joined the Company in 2018 as Director of Global Sales and has since become a vital part of the Aptamer team,...